

CTAG1A Antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI15591

Product Information

Application WB Primary Accession P78358

Other Accession <u>NM 139250</u>, <u>NP 640343</u>

Reactivity Human
Predicted Human
Host Rabbit
Clonality Polyclonal
Calculated MW 17992

Additional Information

Gene ID 1485;246100

Alias Symbol ESO1, LAGE2A

Other Names Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1,

Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2, CTAG1A,

CTAG, CTAG1, ESO1, LAGE2, LAGE2A

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-CTAG1A antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions CTAG1A Antibody - N-terminal region is for research use only and not for use

in diagnostic or therapeutic procedures.

Protein Information

Name CTAG1A

Synonyms CTAG, CTAG1, ESO1, LAGE2, LAGE2A

Cellular Location Cytoplasm

Tissue Location Expressed in testis and ovary and in a wide variety of cancers. Detected in

uterine myometrium. Expressed from 18 weeks until birth in human fetal testis. In the adult testis, is strongly expressed in spermatogonia and in primary spermatocytes, but not in post-meiotic cells or in testicular somatic

cells (at protein level)

References

Chen Y.-T.,et al.Proc. Natl. Acad. Sci. U.S.A. 94:1914-1918(1997). Lethe B.G.,et al.Int. J. Cancer 76:903-908(1998). Wang R.-F.,et al.J. Immunol. 161:3598-3606(1998). De Smet C.,et al.Mol. Cell. Biol. 19:7327-7335(1999). Aradhya S.,et al.Hum. Mol. Genet. 10:2557-2567(2001).

Images



Host: Rabbit

Target Name: CTAG1A

Sample Tissue: HT1080 Whole cell lysate

S

Antibody Dilution: 1.0µg/mlCTAG1A is strongly supported by BioGPS gene expression data to be expressed in

Human HT1080 cells

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.